Guest guest Posted April 11, 2012 Report Share Posted April 11, 2012 Today's Top News 1. Judge hits J & J with $1.1B penalty in Risperdal case<http://links.mkt1985.com/ctt?kn=17 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0 & \ j=MTIzMzM5OTI4S0 & mt=1 & rt=0> By Staton [http://email.cdn.fiercemarkets.com/icons/comment_ico.gif]<http://links.mkt1985.\ com/ctt?kn=203 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0 & j=MTIzMzM5OTI4S0 & mt=1 & rt=\ 0>Comment<http://links.mkt1985.com/ctt?kn=203 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS\ 1 & b=0 & j=MTIzMzM5OTI4S0 & mt=1 & rt=0> | [http://email.cdn.fiercemarkets.com/icons/email_ico.png] <http://links.mkt1985.com/ctt?kn=209 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0 & j=M\ TIzMzM5OTI4S0 & mt=1 & rt=0> Forward<http://links.mkt1985.com/ctt?kn=209 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & \ b=0 & j=MTIzMzM5OTI4S0 & mt=1 & rt=0> | [http://email.cdn.fiercemarkets.com/icons/twitter-small.png] <http://links.mkt1985.com/ctt?kn=184 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0 & j=M\ TIzMzM5OTI4S0 & mt=1 & rt=0> Twitter<http://links.mkt1985.com/ctt?kn=184 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & \ b=0 & j=MTIzMzM5OTI4S0 & mt=1 & rt=0> | [http://email.cdn.fiercemarkets.com/icons/facebook-small.png] <http://links.mkt1985.com/ctt?kn=51 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0 & j=MT\ IzMzM5OTI4S0 & mt=1 & rt=0> Facebook<http://links.mkt1985.com/ctt?kn=51 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & \ b=0 & j=MTIzMzM5OTI4S0 & mt=1 & rt=0> | [http://email.cdn.fiercemarkets.com/icons/linkedin-small.png] <http://links.mkt1985.com/ctt?kn=56 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0 & j=MT\ IzMzM5OTI4S0 & mt=1 & rt=0> LinkedIn<http://links.mkt1985.com/ctt?kn=56 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & \ b=0 & j=MTIzMzM5OTI4S0 & mt=1 & rt=0> & ($JNJ<http://links.mkt1985.com/ctt?kn=128 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=\ 0 & j=MTIzMzM5OTI4S0 & mt=1 & rt=0>) has suffered another Risperdal<http://links.mkt1985.com/ctt?kn=230 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS\ 1 & b=0 & j=MTIzMzM5OTI4S0 & mt=1 & rt=0> defeat. And this one is several times larger than the others: An Arkansas judge slapped the drugmaker with $1.1 billion in penalties for deceptively marketing the antipsychotic drug in his state. The judge's ruling comes after a jury verdict yesterday against the company and its Janssen unit. Like other juries before it, the Arkansas panel found that the company soft-pedaled Risperdal's risks. Once again, it's a marketing letter dispatched to doctors that apparently clinched the deal. After deliberating about three hours, the jury decided that J & J and Janssen broke deceptive trade practice laws with a " Dear Doctor " letter touting Risperdal as safer than its rivals. Using a phrase that he has repeated several times as this case has progressed, Arkansas Attorney General Mc said the jurors agreed that J & J " lied to patients and doctors because they cared more about profits than people. " In a similar case in South Carolina, where a letter to doctors also was deemed deceptive, a judge penalized J & J thousands of dollars for each copy sent, for a total of $327 million. The Arkansas AG had asked for at least $1.25 billion. As Bloomberg notes, this is the third jury verdict against J & J, in lawsuits claiming that state Medicaid programs were duped into overspending on the drug. Besides the South Carolina case, a Louisiana suit ended in $258 million in penalties. J & J has appealed both of those rulings. So, what's next for J & J, which faces other state claims, not to mention a combination federal-and-state settlement of Risperdal probes? " Three losses in a row means the company needs to become more realistic about its exposure and come up with an exit strategy in the form of a settlement, " Carl Tobias, a product-liability law professor, told Bloomberg. But J & J could well appeal this third verdict, too. After the ruling, J & J advanced an argument that sounds like a warm-up for a pre-emption claim--that the FDA, as a federal agency, supersedes state law. " It is our position that an individual state should not penalize a pharmaceutical company for using an FDA-approved package insert or decide for itself whether a company complies with FDA rules, " a spokeswoman told Bloomberg. - read the Bloomberg story<http://links.mkt1985.com/ctt?kn=46 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0\ & j=MTIzMzM5OTI4S0 & mt=1 & rt=0> Related Articles: SC jury finds J & J letter violated consumer laws<http://links.mkt1985.com/ctt?kn=107 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0\ & j=MTIzMzM5OTI4S0 & mt=1 & rt=0> Feds reportedly demand $1.8B in Risperdal marketing probe<http://links.mkt1985.com/ctt?kn=39 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0\ & j=MTIzMzM5OTI4S0 & mt=1 & rt=0> J & J said to settle TX Risperdal case for $158M<http://links.mkt1985.com/ctt?kn=2 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0 & \ j=MTIzMzM5OTI4S0 & mt=1 & rt=0> Witness: J & J memo urged off-label Risperdal push<http://links.mkt1985.com/ctt?kn=89 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & b=0 & \ j=MTIzMzM5OTI4S0 & mt=1 & rt=0> Read more about: & <http://links.mkt1985.com/ctt?kn=128 & ms=NDAxNDM0MgS2 & r=MTg5NDA3MjU5NzcS1 & \ b=0 & j=MTIzMzM5OTI4S0 & mt=1 & rt=0> back to top S. Kalman PhD, RD, FACN Director, BD - Nutrition & Applied Clinical Trials Miami Research Associates 6141 Sunset Drive - Suite 301 Miami, FL. 33143 Direct - Office ext. 5109 Fax Email: dkalman@... Web: www.miamiresearch.com<www.mraclinicalresearch.com/> Linked In: http://www.linkedin.com/in/douglaskalmanphdrd Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.